Skip to main content

Table 5 Student’s t-test analysis of tear proteome from patients diagnosed with ocular GVHD versus control

From: Tear proteomic profile in three distinct ocular surface diseases: keratoconus, pterygium, and dry eye related to graft-versus-host disease

Gene name

Protein

p-value

FDR 5%

FDR 1%

FWER

Control average LFQ log transformed

GVHD average LFQ log transformed

SE of difference

LCN1

Lipocalin-1

6.92E−05

Y

Y

Y

34.6

25.2

1.7

TGM2

Protein-glutamine gamma-glutamyltransferase 2

9.48E−05

Y

Y

Y

24.2

21.7

0.4

LTF

Lactotransferrin; Kaliocin-1; Lactoferroxin-A; Lactoferroxin-B; Lactoferroxin-C

1.97E−04

Y

Y

N

35.4

28.6

1.4

AZGP1

Zinc-alpha-2-glycoprotein

2.29E−04

Y

Y

N

32.3

28.9

0.7

CRISP3

Cysteine-rich secretory protein 3

2.39E−04

Y

Y

N

27.4

21.8

0.6

IGJ

Immunoglobulin J chain

2.83E−04

Y

Y

N

29.8

25.9

0.8

CTSB

Cathepsin B; Cathepsin B light chain; Cathepsin B heavy chain

3.80E−04

Y

N

N

25.4

22.7

0.6

PIGR

Polymeric immunoglobulin receptor; Secretory component

4.62E−04

Y

N

N

30.8

27.3

0.8

LYZ

Lysozyme C

6.12E−04

Y

N

N

33.4

28.2

1.2

LGALS3BP

Galectin-3-binding protein

6.57E−04

Y

N

N

25.0

22.1

0.6

NUCB2

Nucleobindin-2

7.02E−04

Y

N

N

24.7

21.8

0.5

DMBT1

Deleted in malignant brain tumors 1 protein

8.31E−04

Y

N

N

29.4

24.7

1.1

PIP

Prolactin-inducible protein

1.87E−03

Y

N

N

31.3

26.6

1.2

IGHA2

Immunoglobulin heavy constant alpha 2

1.99E−03

Y

N

N

27.4

24.6

0.7

FN1

Fibronectin; Anastellin; Ugl-Y1; Ugl-Y2; Ugl-Y3

2.07E−03

Y

N

N

27.7

24.2

0.9

MSLN

Mesothelin; Megakaryocyte-potentiating factor; Mesothelin, cleaved form

2.44E−03

Y

N

N

25.7

22.2

0.9

CLU

Clusterin; Clusterin beta chain; Clusterin alpha chain; Clusterin

4.16E−03

Y

N

N

27.3

25.4

0.6

IGHA1

Ig alpha-1 chain C region

5.33E−03

Y

N

N

32.5

30.0

0.7

B2M

Beta-2-microglobulin; Beta-2-microglobulin form pI 5.3

5.59E−03

Y

N

N

28.2

24.9

1.0

DBNL

Drebrin-like protein

6.22E−03

N

N

N

21.5

20.5

0.3

PRR4

Proline-rich protein 4

7.24E−03

N

N

N

31.1

24.5

2.0

IGHA2

Ig alpha-2 chain C region

7.43E−03

N

N

N

26.2

23.2

0.5

PSAP

Proactivator polypeptide; Saposin-A; Saposin-B-Val; Saposin-B; Saposin-C; Saposin-D

7.65E−03

N

N

N

24.0

22.7

0.4

SLPI

Antileukoproteinase

9.52E−03

N

N

N

27.1

24.8

0.8

CBR1

Carbonyl reductase [NADPH] 1

1.50E−02

N

N

N

22.7

20.8

0.6

TUBB4B; TUBB4A

Tubulin beta-4B chain; Tubulin beta-4A chain

1.65E−02

N

N

N

27.0

25.2

0.6

RNH1

Ribonuclease inhibitor

1.69E−02

N

N

N

23.0

21.9

0.3

HNRNPK

Heterogeneous nuclear ribonucleoprotein K

2.08E−02

N

N

N

24.1

20.6

1.1

PRDX6

Peroxiredoxin-6

2.94E−02

N

N

N

23.9

22.0

0.7

IGHV3-7@

Immunoglobulin heavy variable 3–7

3.30E−02

N

N

N

22.6

21.0

0.7

CST3

Cystatin-C

3.94E−02

N

N

N

24.0

21.6

1.0

PHGDH

D-3-phosphoglycerate dehydrogenase

4.14E−02

N

N

N

21.0

19.0

0.6

IGHV3-72

Immunoglobulin heavy variable 3–72

4.17E−02

N

N

N

23.4

22.4

0.5

IGHV3OR16-12

Immunoglobulin heavy variable 3/OR16-12 (non-functional)

4.34E−02

N

N

N

23.5

21.8

0.7

IGKV2D-24; IGKV2-24

Immunoglobulin kappa variable 2D-24 (non-functional), Immunoglobulin kappa variable 2–24

4.71E−02

N

N

N

22.9

22.1

0.3

  1. Proteins with decreased abundance in GVHD in comparison with controls are shown
  2. FDR: false discovery rate. FEWR: family-wise error rate (Holm-Sidak method). Y: yes, still significant after multiple comparisons correction. N: no, not significant after multiple comparisons correction. SE: standard error. @ Immunoglobulin cluster (P01780; A0A0B4J1V1; P01762; P01763; A0A0C4DH32; A0A075B7F0)
Back to article page

Clinical Proteomics

ISSN: 1559-0275